Arcutis (ARQT) Q1 2026 earnings review
Robust YoY Growth Masked by Expected Seasonal Dip
Arcutis delivered a 65% YoY revenue increase to $105.4M in Q1 2026, driven by continued robust demand for the ZORYVE franchise. However, revenue declined 17% sequentially from Q4 2025, a Reversing trend heavily telegraphed by management due to typical Q1 patient deductible resets and insurance changes. While the company maintained positive operating cash flow of $2.2M, bottom-line profitability was Reversing; Net Loss fell back to $11.3M after a profitable H2 2025, pressured by a $10M R&D milestone payment for ARQ-234 and higher SG&A to fund sales force expansion. Management reaffirmed FY26 revenue guidance of $480-$495M, indicating confidence that sequential growth will return in Q2.
🐂 Bull Case
The foam formulation (0.3%) generated $49.6M, representing nearly half of Q1 product revenue. This validates the 'portfolio effect' thesis where multiple formulations expand total prescriber volume.
Despite a sequential revenue drop and a $10M R&D milestone payment, Arcutis stayed operating cash flow positive (+$2.2M), proving the financial discipline and operating leverage established in 2025.
🐻 Bear Case
The 17% sequential revenue decline and return to a Net Loss (-$11.3M) show that gross-to-net pricing remains highly sensitive to Q1 deductible resets, creating a bumpy earnings trajectory.
SG&A rose to $74.1M (up from $64.0M a year ago) due to the dermatology sales force expansion and a new primary care build-out. If these investments do not yield high ROI, margins will compress.
⚖️ Verdict: ⚪
Neutral. The YoY growth trajectory remains highly compelling, and maintaining positive cash flow during a seasonally weak quarter is a major victory. However, stepping back into net loss territory due to rising SG&A costs and R&D milestones means investors must trust management's H2 2026 execution.
Key Themes
ZORYVE Foam 0.3% Becomes the Franchise Engine
Accelerating. ZORYVE topical foam 0.3% is now the undisputed primary revenue driver, contributing $49.6M in Q1 2026. This easily outpaced the original cream 0.3% ($32.7M) and cream 0.15% ($21.7M). The rapid adoption of foam for scalp and body psoriasis validates the company's life cycle management strategy.
Sales Force Expansion Targeting Primary Care
Stable. Arcutis completed its dermatology sales force expansion in early May and officially initiated the build-out of a targeted primary care and pediatric organization, hiring Katie Swolfs as head of the Primary Care Franchise. Taking primary care promotion in-house represents a massive TAM expansion, though it carries execution risk in a diffuse market.
Escalating Operating Expenses
Decelerating margin profile in the short term. SG&A expenses jumped to $74.1M (vs $64.0M in 25Q1), driven by commercialization efforts and compensation. R&D spiked to $30.6M (vs $17.5M in 25Q1), entirely due to a $10M milestone payment to Ducentis for the ARQ-234 Phase 1 dosing. This spend pushed the company back into a net loss position for the quarter.
Pediatric Label Expansion Progress
Accelerating. The company submitted an sNDA for ZORYVE cream 0.05% for infants (3-24 months) with mild to moderate atopic dermatitis, supported by compelling INTEGUMENT-INFANT data showing rapid itch improvement in 10 minutes. Additionally, the June 29, 2026 PDUFA date for ZORYVE cream 0.3% in pediatric psoriasis (ages 2-11) sets up a near-term catalyst.
Q1 Seasonality Highlights Gross-to-Net Fragility
Reversing. While management telegraphed the Q1 revenue dip in their 25Q4 earnings call, the 17% sequential drop (from $127.5M to $105.4M) highlights the ZORYVE franchise's vulnerability to Q1 deductible resets. The heavy reliance on co-pay assistance early in the year depresses net recognized revenue, placing heavy pressure on Q2-Q4 to hit annual targets.
Other KPIs
Accelerating. Though a small portion of the total $105.4M mix, this newly launched low-concentration formulation for pediatric atopic dermatitis represents the leading edge of Arcutis' strategy to capture the pediatric market.
Stable. Up slightly from $221.3M at the end of 2025. By funding operations, milestone payments, and sales force expansions out of its own operating cash flow (+$2.2M), the company minimizes dilution risks.
Guidance
Decelerating percentage growth, but massive absolute dollar additions. The midpoint of $487.5M implies ~31% YoY growth compared to the estimated $372M generated in FY25. Maintaining this guidance despite the $105.4M Q1 print means Arcutis must average ~$127M per quarter for the rest of the year.
Key Questions
Bridge to FY26 Revenue Guidance
With Q1 coming in at $105.4M, achieving the $487.5M midpoint requires significant acceleration. How much of this ramp is reliant on the new primary care sales force versus organic dermatology growth and new label expansions?
Primary Care ROI Timeline
As the primary care and pediatric sales team build-out begins, what is the expected timeline for these newly hired representatives to become profitable, given the notoriously long sales cycles outside of specialty dermatology?
Margin Outlook Post-Milestone
With the $10M Ducentis milestone now paid, how should we model baseline R&D expenses for the remainder of 2026 as the ARQ-234 Phase 1a/1b trial ramps up?